Categorías
-
Adhesives
6
Amines
115
Amino Acids
207
Analytical Reagents
750
Antibiotics
270
Bioactive Small Molecules
798
Aroma Chemicals
242
Biochemicals
1142
Boronic Acids
4
Buffers
104
Building Blocks
2162
Carbohydrates
191
Catalysts
117
Chiral Compounds
78
Coccus nucifera oil
0
Detergents
62
Diagnostic Raw Materials
271
Flavours and Fragrance Materials
234
Fluorinated Products
67
Furans
7
Gases in Solution
51
Grignard Reagents
31
HPLC Reagents
8
Imidazoles
18
Indoles
48
Inorganic Chemicals
357
Ion-Pair Reagents
23
Ligands
81
Organics
1628
Oxazoles
3
Peptide Reagents
99
Phenols
55
Picolines
0
Piperazines
13
Pyrazines
3
Pyridines
65
Pyrimidines
36
Quaternary Ammonium salts
45
Reagents
114
Research Organics & Inorganics
885
Salts
308
Sealing Compounds
1
Sherclin
1
Solvents
132
Stains & Indicators
322
Sugars
66
Tailor-made solutions
1
Testing Standards
4
Uncategorised
22
Water Analysis
13
Naproxen
(25190315 | 22204-53-1)
CAS: | 22204-53-1 |
---|---|
Fórmula molecular: | C14H14O3 |
Peso molecular: | 230.26 |
Disponibilidad: | En stock |
---|---|
Descargas: | | |
Este producto está sujeto a un recargo peligroso. La cantidad exacta será confirmada por nuestro equipo de ventas.
25190315-5g | 5g | £51.40 | |
Pedido bulk |
25190315-5g | 5g | €72.00 | |
Pedido bulk |
25190315-5g | 5g | $77.10 | |
Pedido bulk |
Ficha de datos de seguridad
Certificado de análisis
Detalle del producto
Product Code | 25190315 | ||||
Product Name | Naproxen | ||||
Categories | Bioactive Small Molecules Research Organics & Inorganics | ||||
CAS | 22204-53-1 | ||||
Molecular Formula | C14H14O3 | ||||
Molecular Weight | 230.26 | ||||
Storage Details | Ambient | ||||
Harmonised Tariff Code | 29189990 |
Especificaciones del producto
Melting Point | 154 - 158 Deg C | ||||
Specific rotation | +83 to +89.5 | ||||
Heavy metals | <0.002% | ||||
Loss on Drying | <0.5% | ||||
Assay | 98.5 - 101.5% | ||||
Appearance | White crystalline powder |
Información de seguridad
Pictograms |
|
||||
Signal word | danger | ||||
Hazard statements |
|
||||
Precautionary statements |
|